Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19open access
- Authors
- Kang, Dong-Hoon; Na, Joo-Young; Yang, Jun-Ho; Moon, Seong-Ho; Kim, Sung-Hwan; Jung, Jae-Jun; Cha, Ho-Jeong; Ahn, Jong-Hwa; Park, Yong-Whi; Cho, Sang-Yeong; Yu, Ho-Kyung; Lee, Soo-Hee; Park, Mi-Yeong; Kim, Jong-Woo; Byun, Joung-Hun
- Issue Date
- Mar-2022
- Publisher
- MDPI
- Keywords
- COVID-19; vaccination; giant cell myocarditis
- Citation
- Medicina (Kaunas, Lithuania), v.58, no.3
- Indexed
- SCIE
SCOPUS
- Journal Title
- Medicina (Kaunas, Lithuania)
- Volume
- 58
- Number
- 3
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/1571
- DOI
- 10.3390/medicina58030449
- ISSN
- 1010-660X
1648-9144
- Abstract
- A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical signs or have laboratory findings of concomitant infection before or after vaccination. Heart transplantation was performed because her heart failed to recover with venoarterial extracorporeal oxygenation support. Organ autopsy revealed giant cell myocarditis, possibly related to the vaccines. Clinicians may have to consider the possibility of the development of giant cell myocarditis, especially in patients with rapidly deteriorating cardiac function and myocarditis symptoms after COVID-19 vaccination.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.